Tagged: retinitis pigmentosa
For patients who have lost their sight to various eye diseases, artificial retina technology allows them to experience limited vision once more.
The external parts of the artificial retina device include glasses with a mounted camera and a small computer.
The device also includes an electrode implanted onto the patient’s retina. When the camera “sees” an image, the computer is able to translate these into a pattern of neural signals. This pattern is then transmitted to the implanted electrode, and directly stimulates the optic nerve. These signals are then able to be processed by the brain and interpreted as very rudimentary images.
The first artificial retina to be implanted in a patient, known as Argus I, included only sixteen electrodes that stimulated the optic nerve. However, the patient with this implant was still able to tell the differences between light and dark, and could make out basic shapes. The newer version of the technology, Argus II, now includes sixty electrodes. However, it is still limited in that patients can only tell the differences between light and dark areas, and can only see shapes, outlines, and blurs, and not detailed images. Regardless, this is a large improvement over no sight, and patients with the implant are satisfied with simply a partial regain of their vision, and are hopeful that the technology will continue to improve. As of late, a third model of the artificial retina is in development, and will include over 200 electrodes.
Though the project began almost ten years ago, the implant has recently been approved for patients in Europe. The company has not yet submitted approval to the FDA, but hopes to do so by the end of this year.
Second Sight – How is Argus II Designed to Produce Sight?
CBS News HealthPop – First Artificial Retina Approved in Europe
US Department of Energy Office of Science – About the Artificial Retina Project
Vision is one of the most impressive functions of the human brain. It interprets nothing but electromagnetic waves and paints a glorious picture of our daily existence from the scattered chaotic sea of intertwining light waves that we call home. Many see their vision deteriorate and the world blur as time goes on and these problems can be corrected by optometry, but blindness comes on like a relentless infidel for more than two million people worldwide in the form of retinitis pigmentosa (RP). RP is a heritible genetic disorder that leads to degeneration and loss of function in the retina’s photoreceptor cells, and can lead to full blindness in a matter of years. There is no cure or treatment for RP, but new research may change that very soon.
Vision starts in the photoreceptor when light activates rhodopsin, a G-protein coupled receptor pigment consisting of light sensitive opsin and retinal. Light triggers a conformational change in retinal that kick starts a G-coupled visual cascade and the flow of visual information to the brain. In retinitis pigmentosa, rhodopsins in the photoreceptors become insensitive to light starting in the rod cells, and blindness sets in gradually. Rod cells are used in low light and deteriorate first, leading to night blindness, and dysfunction in cone cells used for color vision and acuity sets in until full blindness plagues the individual. Fortunately, a team of French scientists has investigated this degradation and has found a way to combat it by reactivating the photoreceptor cells through genetics. Their study was featured in the July 23rd issue of Science.
The scientists isolated an achaebacterial rhodopsin analog called halorhodopsin that functions in the yellow and green wavelength range. They then introduced a halorhodopsin encoding gene into retinitis pigmentosa model mice via a viral vector and also created a control group. In their experiments, it was found that both slow and fast degrading retinal cells in the experimental mice regained their light sensitivity in response to integration of halorhodopsin into their insensitive photoreceptor cells. Electrical responses were recorded from ganglion cells (the third tier cell in the visual cascade) and healthy photoreceptor spikes were observed in response to light stimulation. Most importantly, lateral inhibition (the mechanism by which the brain discriminates edges of objects) was fully preserved, while mono-directional movement was retained. Halorhodopsin mice also performed significantly better than the control RP mice in a battery of visually guided tasks, demonstrating that their photoreceptors had been successfully resensitized by halorhodopsin integration. The scientists also tested the resensitizing ability of halorhodopsin on cultured human retinal cells. They were successful in integrating halorhodopsin into human cells via viral vectors, but could not conduct any clinical trials. However, photoreceptors expressing halorhodopsin demonstrated photocurrents and photovoltages that would be adequate to restore human vision.
This opens the door to treatment of retinitis pigmentosa in the genes – the same place where it starts. Although halorhodopsin therapy will not fully restore all wavelengths in human vision, it can still serve as a tool to bring restore vision in the blind through optical devices. For example, an RP patient could be treated with halorhodopsin gene thearpy, then outfitted with a device that images the visual field and translates it into halorhodopsin recognizable wavelengths. This light mosaic is then projected onto the patient’s eyes and the can “see” what is in front of them. The supplied image of the device is from a perspective article in the beginning of the current issue of Science.
Seeing the Light of Day - Science (Perspective)
Genetic Reactivation of Cone Photoreceptors Restores Responses in Retinitis Pigmentosa - Science (Research Article)